Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 16/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19305940 | 0.83 | HTR7 (1.00) | HTR7MEN1KMT2A | |
| SCHEMBL19306250 | 0.79 | HTR7 (0.67) | HTR7MEN1KMT2AGFER | |
| SCHEMBL19306453 | 0.79 | HTR7 (0.63) | HTR7MEN1KMT2AGFER | |
| SCHEMBL19306541 | 0.77 | HTR7 (1.00) | HTR7 | |
| SCHEMBL19306372 | 0.77 | HTR7 (1.00) | HTR7 | |
| SCHEMBL19306509 | 0.76 | HTR7 (1.00) | HTR7MEN1KMT2A | |
| SCHEMBL19317336 | 0.75 | HTR7 (0.79) | HTR7MEN1KMT2A | |
| SCHEMBL19306211 | 0.74 | HTR7 (0.66) | HTR7MEN1KMT2AGFER | |
| SCHEMBL28254564 | 0.74 | HTR7 (0.67) | HTR7MEN1KMT2AGFER | |
| SCHEMBL19317337 | 0.74 | HTR7 (0.73) | HTR7MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426246-B1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RES INST (TW) | 2024-05-01 | — | — | EP | disclosed |
| CN-108883099-B | Thiazolidinone compounds and use thereof | 石全 | 2021-09-28 | — | — | CN | disclosed |
| US-10544113-B2 | Thiazolidinone compounds and use thereof | NATIONAL HEALTH RESEARCH INSTITUTE (TW) | 2020-01-28 | — | — | US | disclosed |
| US-10544113-B2 | Thiazolidinone compounds and use thereof | NATIONAL HEALTH RESEARCH INSTITUTE (TW) | 2020-01-28 | — | — | US | disclosed |
| EP-3426246-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | National Health Research Institutes (TW) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017155910-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2017-09-14 | — | — | WO | disclosed |
| US-20170253569-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2017-09-07 | — | — | US | disclosed |
| US-20170253569-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2017-09-07 | — | — | US | disclosed |
| US-20170253569-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544113-B2 | Thiazolidinone compounds and use thereof | OPRL1, OPRD1, OPRK1 | HTR7 106/4885MEN1 4566/4885KMT2A 3536/4885 |
| US-20170253569-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | OPRL1, OPRD1, OPRK1 | HTR7 106/4885MEN1 4566/4885KMT2A 3536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.